"Comparison of New Anti-TAR Constructs for Anti-HIV Gene Therapy."

According to an abstract submitted by the authors to the Keystone Symposia on Molecular and Cellular Biology entitled AIDS Pathogenesis, sponsored by Abbott Laboratories and the Director's Sponsor Fund, held April 8-13, 1997, in Keystone, Colorado, "A target for anti-HIV gene therapy is the Tat activation response (TAR) region of the HIV genome. Blocking Tat trans-activation could potentially reduce viral burden in patients and increase their overall health and longevity. An antisense TAR can specifically bind TAR to block Tat, whereas a decoy (sense) TAR will bind Tat and prevent it from binding TAR. We constructed an antisense TAR (where antisense TAR is driven by a tRNA promoter in a...

Want to see the full article?

• Purchase this article for only $3.00